drugset / Trial / NCT06085742
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a non-randomized, single arm phase 2 trial of oral CMC based on conversion of doses that would be delivered with conventional metronomic CMF chemotherapy.
Timeline
- Start
- 2023-11-22
- Primary completion
- 2034-09
- Completion
- 2034-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 825 mg/m2 | Oral |
| Subject | Cyclophosphamide | Other / unclassified | 60 mg/m2 | Oral |
| Subject | Methotrexate | Small molecule | 10 mg/m2 | Oral |